The results revealed that CD8+ T cells pretreated with the culture medium (CM) from siTACC3 or shTACC3 HCC cells presented enhanced antitumor function, whereas those pretreated with the CM from ovTACC3 HCC cells presented significantly restricted tumor-killing capacity (Fig. 3b, c and Supplementary Fig. 4j‒l). The gene discussed is CD8A; the disease is neoplasm.